European Union - English - EMA (European Medicines Agency)

laboratorios hipra s.a. - live attenuated bovine respiratory syncytial virus (brsv), strain lym-56 - immunologicals for bovidae, cattle, live viral vaccines, bovine respiratory syncytial virus (brsv) - cattle - active immunisation of cattle to reduce virus shedding and respiratory clinical signs caused by bovine respiratory syncytial virus infection.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratorios león farma s.a. - ethinylestradiol 3,474 mg; etonogestrel 11 mg - vaginal delivery system - 0,120 mg/24 h - 0,015 mg/24 h - etonogestrel 11 mg; ethinylestradiol 3.474 mg - vaginal ring with progestogen and estrogen

European Union - English - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies).to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies.to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies).mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

European Union - English - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - pigs - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b.- to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratorios liconsa s.a. - tapentadol tartrate 167,81 mg - eq. tapentadol 100 mg - prolonged-release tablet - tapentadol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratorios liconsa s.a. - tapentadol tartrate 251,715 mg - eq. tapentadol 150 mg - prolonged-release tablet - tapentadol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratorios liconsa s.a. - tapentadol tartrate 335,62 mg - eq. tapentadol 200 mg - prolonged-release tablet - tapentadol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratorios liconsa s.a. - tapentadol tartrate 41,9525 mg - eq. tapentadol 25 mg - prolonged-release tablet - tapentadol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratorios liconsa s.a. - tapentadol tartrate 419,525 mg - eq. tapentadol 250 mg - prolonged-release tablet - tapentadol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratorios liconsa s.a. - tapentadol tartrate 83,905 mg - eq. tapentadol 50 mg - prolonged-release tablet - tapentadol